Very glad to present our data on pre-clinical validation for the discovery of a novel CAR-T therapy for mutCALR Myelofibrosis in such an amazing meeting #ESHMPN2024

Many thanks to Claire Roddie, Martin Pule, Jon Lambert and Beth Psaila for their ongoing support

UCL Cancer Institute

Happening now at #ONSCongress . Moffitt's Sara Tinsley-Vance, PhD presents on therapeutic strategies for the treatment of #Myelofibrosis , the MPN with the shortest survival and the highest symptom burden. Learn more 👉 bit.ly/3y0NgCO #ONS24

The results of the first clinical trial to explore activin receptor ligand traps of drugs in MF - Hagop Kantarjian,MD
MD Anderson Cancer Center Prithviraj Bose Haematologica

#Cancer #Cancer Research #ClinicalTrial #Hematology #Myelofibrosis #OncoDaily #Oncology

oncodaily.com/54586.html

We just caught up with Mary Frances McMullin from Queen's University, who gave an insight into the management of #Myelofibrosis in patients w/ anemia, the current BSH guidelines for diagnosis & evaluation of prognosis of the disease, & more!

#BSH2024 #HemOnc #MPNsm BSH - Haematology

📌 Mutations in Hematology

𝐉𝐀𝐊𝟐 𝐌𝐮𝐭𝐚𝐭𝐢𝐨𝐧
- Idiopathic Myelofibrosis
- Essential Thrombocythemia
- Polycythemia Vera

𝐁𝐂𝐑/𝐀𝐁𝐋 𝐌𝐮𝐭𝐚𝐭𝐢𝐨𝐧𝐬
- CML

𝐏𝐈𝐆𝐀 𝐠𝐞𝐧𝐞 𝐦𝐮𝐭𝐚𝐭𝐢𝐨𝐧
- Paroxysmal Nocturnal Hemoglobinuria

#CLUEmydiaHEMA

We will present the first comprehensive study comparing different ruxolitinib strategies in myelofibrosis undergoing transplant as oral at #EHA2024 European Hematology Association by Kristin Rathje #mpnsm

See you in Madri❤️🇪🇸 YoungEHA

Management of paroxysmal nocturnal hemoglobinuria in CALR mutated post-essential thrombocythemia myelofibrosis: A case report
buff.ly/3UbndjJ

At the upcoming #ASCO24 annual meeting, we’re presenting new efficacy and safety data from our Phase 3 MANIFEST-2 trial evaluating our investigational BET inhibitor in combination with a JAK inhibitor in #myelofibrosis . Learn more: bit.ly/3U9VujH

The best and only curative treatment for patients with myelofibrosis is allogeneic hematopoietic cell transplant🙏

Refer patients for consult early, consultation does not mean instant transplantation.

We are very proud of Lisa, Nurse Specialist, in completing her silver QI on frailty assessment in patients with Myelofibrosis. Absolutely delighted to hear that she won an award for best QI project in a very strong group. Fantastic effort! 👏👏

John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai & The Tisch Cancer Institute Raajit Rampal, M.D.Ph.D., MD, PhD, of @sloan_kettering, & Michael Savona, MD, of VUMC Department of Medicine discuss disease progression, symptoms, and outcomes in patients with #myelofibrosis .
expertperspectives.com/disease-progre…

Scoop from Adam Feuerstein ✡️:

The FDA has issued a warning letter to physicians involved in clinical trials of pelabresib, a treatment being developed by Morphosys, noting an imbalance in the number of patients who progress from myelofibrosis to acute myeloid leukemia.

The drug…

Interesting interview below w/ Bristol Myers Squibb CEO. One of the areas where they are decreasing investment: 'one asset we are deprioritizing is a BET inhibitor, 986158. It was a product we were developing in myelofibrosis and frankly, as we look at it, it simply didn’t meet…

This episode of Oncology Today with Dr Neil Love features an interview with Dr Naveen Pemmaraju about updated findings from ASH 2023 on the management of myelofibrosis, polycythemia vera and essential thrombocythemia.

bit.ly/44n82cc

MorphoSys is dealing with an emerging safety issue related to pelabresib, the experimental treatment for myelofibrosis, STAT has learned. trib.al/atWxmHk

John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai & The Tisch Cancer Institute Raajit Rampal, M.D.Ph.D., MD, PhD, of @sloan_kettering, & Michael Savona, MD, of VUMC Department of Medicine discuss disease progression, symptoms, and outcomes in patients with #myelofibrosis .
expertperspectives.com/disease-progre…

WATCH: Prithviraj Bose, MD, discusses the key findings from the COMFORT I and II trials and how the overall survival data has impacted the way he manages patients with #myelofibrosis . MD Anderson Cancer Center

targetedonc.com/view/key-findi…

Researchers from the US reported the unique case of a patient with postessential thrombocythemia, myelofibrosis, and paroxysmal nocturnal hemoglobinuria who was treated with hematopoietic cell transplantation.

Read more: brnw.ch/21wJ6vu

#RareDisease

Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting $KPTI healthstockshub.com/news/nasdaq/kp…

Abstract: Attention! Karyopharm Therapeut ($KPTI 🚀Stock Price: $1.055) reveals a major update on Selinexor for Myelofibrosis. Game changer?

Click for More: ainvest.onelink.me/MpR9/33tz0xdi

#Trending #onlinetrading #tradeideas